# TRPV1 Downregulation Impairs Prostate Cancer Growth: Functional and Translational Insights from Cellular and In Vivo Models

**Authors:** Belén G. Sánchez, José M. Mora-Rodríguez, Alicia Bort, Ana Palacín, Carlos Sánchez-Rodríguez, Manuel Sánchez-Chapado, Julie Courraud, Jerome Zoidakis, Inés Díaz-Laviada

PMC · DOI: 10.7150/ijbs.125429 · International Journal of Biological Sciences · 2026-01-22

## TL;DR

This study shows that TRPV1, a receptor for capsaicin, plays a key role in prostate cancer growth and could be a new target for diagnosis and treatment.

## Contribution

The study identifies TRPV1 as a novel regulator of prostate cancer progression and a mediator of capsaicin's antiproliferative effects.

## Key findings

- TRPV1 knockdown and capsaicin treatment reduced cell proliferation markers and increased cell cycle inhibitors.
- TRPV1 expression correlated with cancer stem cell markers in both mouse models and human prostate samples.
- Capsaicin supplementation in mice reversed high-fat diet-induced prostate cancer progression.

## Abstract

The transient receptor potential vanilloid 1 (TRPV1), the canonical capsaicin (CAP) receptor, has been implicated across diverse pathologies, yet its role in prostate cancer (PCa) remains elusive. Here, we uncover TRPV1 as a key regulator of PCa progression and a mediator of CAP's antiproliferative effects. Through a comprehensive strategy combining proteomic profiling, Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mouse modeling, and validation in human prostate biopsies, we assessed TRPV1 expression, its functional role, and its association with tumor markers. Both proteomic analysis and Western blotting of TRPV1-silenced cells revealed reduced expression of PCNA, Cyclin B1, and AURKA, along with elevated levels of the cell cycle inhibitor p21. Similarly, CAP treatment resulted in comparable changes in the proteomic profile. Functional assays demonstrated that both TRPV1 knockdown and CAP exposure significantly impaired cell cycle progression and mitosis. Moreover, sustained CAP treatment led to a reduction in TRPV1 expression, further supporting its oncogenic role. In TRAMP mice, a high-fat diet feeding elevated plasma PSA levels and TRPV1 expression in the prostate, whereas CAP supplementation reversed these effects. Importantly, TRPV1 expression correlated positively with cancer stem cell markers in both murine models and human samples. Collectively, our results reveal that TRPV1 is not only overexpressed in PCa but also contributes to proliferation regulation and stemness features, positioning it as a potential diagnostic and prognostic biomarker for prostate cancer.

## Linked entities

- **Genes:** TRPV1 (transient receptor potential cation channel subfamily V member 1) [NCBI Gene 7442], PCNA (proliferating cell nuclear antigen) [NCBI Gene 5111], CycB (Cyclin B) [NCBI Gene 37618], AURKA (aurora kinase A) [NCBI Gene 6790], CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026]
- **Chemicals:** capsaicin (PubChem CID 1548943)
- **Diseases:** prostate cancer (MONDO:0005159)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Npepps (aminopeptidase puromycin sensitive) [NCBI Gene 19155] {aka AAP-S, MP100, Psa, goku}, Trpv1 (transient receptor potential cation channel, subfamily V, member 1) [NCBI Gene 193034] {aka OTRPC1, TRPV1alpha, TRPV1beta, VR-1, Vr1}, Ccnb1 (cyclin B1) [NCBI Gene 268697] {aka Ccnb1-rs1, Ccnb1-rs13, CycB1, Cycb-4, Cycb-5, Cycb1-rs1}, Aurka (aurora kinase A) [NCBI Gene 20878] {aka AIRK1, ARK-1, Ark1, Aurora-A, Ayk1, IAK}, Cdkn1a (cyclin dependent kinase inhibitor 1A) [NCBI Gene 12575] {aka CAP20, CDKI, CIP1, Cdkn1, P21, SDI1}, Pcna (proliferating cell nuclear antigen) [NCBI Gene 18538]
- **Diseases:** Adenocarcinoma (MESH:D000230), cancer (MESH:D009369), PCa (MESH:D011471)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12905635/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12905635/full.md

## References

59 references — full list in the complete paper: https://tomesphere.com/paper/PMC12905635/full.md

---
Source: https://tomesphere.com/paper/PMC12905635